Assessing AtaiBeckley's Valuation: Price-to-Book Ratio and DCF Model Reveal Insights

AtaiBeckley (ATAI) shares have seen a 153.3% total shareholder return over the past year, but a 30.6% decline in the last 90 days. The company's 8.8x price-to-book ratio is considered good value compared to peers but expensive compared to the broader US pharmaceuticals industry. A DCF model suggests a deep discount, making it a buying opportunity for investors.